• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS spectrums >Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder
【24h】

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder

机译：重度抑郁症患者使用地斯拉法辛50 mg / d可预测功能性反应和缓解

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. The predictive value of early functional improvement for treatment success at week 8 was assessed in a pooled analysis in patients with major depressive disorder (MDD). Methods. Data were pooled from 7 double-blind studies in adult patients with MDD randomly assigned to desvenlafaxine 50 mg/d or placebo. Four levels of treatment success were determined at week 8 for patients with baseline Sheehan Disability Scale (SDS) score 12 (N = 2156): functional response (SDS ≤12 and ≥50% improvement in SDS), functional/depression response (SDS ≤12 and ≥50% improvement in both SDS and 17-item Hamilton Rating Scale for Depression [HAM-D17] score), functional remission (SDS, 7), and functional/depression remission (SDS 7 and HAM-D17 ≤7). Week 2 improvement in SDS was evaluated as a predictor of later functional response/remission using receiver operating characteristic analysis. Odds ratios (ORs) of the predictability of improvement thresholds were computed from a logistic regression model. Results. The proportion of patients achieving each level of treatment success was significantly greater for patients treated with desvenlafaxine (40%, 32%, 23%, 15%, respectively) vs placebo (31%, 22%, 17%, 10%; all P ≤ 0.002). Early change in SDS was a highly significant predictor of functional response/remission (ORs, 0.958-0.970; all P0.0001). Discussion. Patients' early functional response to desvenlafaxine 50 mg/d is predictive of treatment success.
机译：背景。在重大抑郁症（MDD）患者的汇总分析中评估了第8周早期功能改善对治疗成功的预测价值。方法。数据来自7项针对成年MDD患者的随机对照研究，这些患者随机分配给地塞拉法辛50 mg / d或安慰剂。对于基线希恩残疾量表（SDS）得分> 12（N = 2156）的患者，在第8周确定了四个治疗成功水平：功能反应（SDS≤12和SDS改善≥50％），功能/抑郁反应（SDS） SDS和17项汉密尔顿抑郁量表[HAM-D17]评分，功能缓解（SDS，7）和功能/抑郁缓解（SDS <7和HAM-D17≤7）的SDS和17项目汉密尔顿评分量表的改善分别≤12和≥50％ ）。使用接收器工作特征分析，将第2周SDS的改善评估为以后功能响应/缓解的预测指标。从逻辑回归模型计算改善阈值可预测性的几率（OR）。结果。与使用安慰剂（分别为40％，32％，23％，15％）和安慰剂（分别为31％，22％，17％，10％）相比，接受地斯拉法辛治疗的患者达到各个治疗成功水平的比例明显更高。 ≤0.002）。 SDS的早期改变是功能反应/缓解的高度重要预测指标（OR为0.958-0.970;所有P <0.0001）。讨论。患者对地斯拉法辛50 mg / d的早期功能反应可预示治疗成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号